Drug Interactions Diabetics Should Avoid

Patients with diabetes have a higher pill burden than the general population, so pharmacists should pay particular attention to potential drug interactions with antidiabetic agents.

Drug interactions may decrease medication efficacy or increase toxicity, and greater pill burden challenges adherence and adds to adverse effects.

Past research has shown that the benefits of carefully selected cardiovascular medications outweigh their risks. In addition, pharmacists should know the following facts:

·         Sulfonylureas, thiazolidinediones, meglitinides, and dipeptidyl-peptidase-4 inhibitors (DDP-4s) are most susceptible to interactions.

·         Glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose transport protein (SGLT-2) inhibitors are least affected by drug interactions.

·         Clinicians should consider altered absorption and transporter action, herbal supplements, and cytochrome (CYP) P450 interactions when selecting medications for patients with diabetes.

A team of researchers recently addressed the pharmacodynamic and pharmacokinetic interactions of antidiabetic drugs in a new study published in the April 2016 issue of Therapeutic Advances in Endocrinology and Metabolism.

The study authors conducted a literature review using the terms drug interactions, diabetes mellitus, type 2/drug therapy, humans, and hypoglycemic agents/adverse effects. They also created a summary document that reminded pharmacists about the likelihood of drug interactions concisely and thoroughly.

Here were some of their significant findings:

·         Sulfonylurea-induced hypoglycemia is worsened by co-administration with azole antifungals, clarithromycin, verapamil, angiotensin-converting enzyme (ACE) inhibitors, DPP-4s, and GLP-1 agonists.

·         Metformin toxicity is more likely with anticholinergics because of increased absorption and nephrotoxic agents (eg, iodinated contrast media).

·         Thiazolidinedione toxicity is heightened by CYP P450 2C8 inhibitors (eg, ketoconazole, gemfibrozil, rifampicin, fluvoxamine, and trimethoprim).

·         Saxagliptin concentration is affected by CYP3A4 inhibitors and inducers, and ACE inhibitors increase the risk of bradykinin-induced angioedema.

·         Ginseng induces CYP3A4 (decreasing glibenclamide, pioglitazone, meglitinides, sitagliptin, and saxagliptin concentrations) and stimulates insulin secretion.

·         St. John’s wort induces CYP3A4, 1A2, 2D6, and 2E1 (decreasing sulfonylureas, thiazolidinediones, meglitinides, and DPP-4 inhibitors) and induces p-glycoprotein pumps.

·         Sulfonylureas, thiazolidinediones, and meglitinides are affected by hepatic enzyme interactions, metformin toxicity is mediated by nephrotoxicity, and dipeptidyl-peptidase-4 inhibitors are less affected by hepatic enzymes.

Jeannette Y. Wick, RPh, MBA, FASCP

Comments

Post a Comment

Cool

Popular posts from this blog

10 EARLY PREGNANCY SYMPTOMS WHICH APPEAR BEFORE MISSING A PERIOD

Many women experience the first pregnancy symptoms days before missing a period as a result of the shift in the hormones, which causes certain changes in the body. The first pregnancy symptoms can occur up to a week before a sufficient number of pregnancy hormones starts to circulate in the body to give a positive result on the pregnancy test. Here are the earliest symptoms of pregnancy, which appear before a missed period. Pregnancy Symptoms Cramping Cramping is one of the earliest symptoms of pregnancy. The cramps can be noticed when your embryo implants into your uterus. This sign can be easily mistaken for menstrual cramps. Fatigue Increased levels of progesterone can make you feel exhausted. Fatigue is usually experienced as early as a week after ovulation. After you ovulate, the levels of progesterone rise, regardless of being pregnant or not. However, if you are not pregnant your progesterone levels will soon decrease. After ovulation, if you start feeling tired, and if t...
Read more

First Birth Control For Men, An Injection To The Groin, Will Be Available Soon

The use of contraceptives has been largely associated with women, but birth control for men might soon be available for use after Indian scientists announced that they have successfully completed clinical trials on the world’s first male birth control injection. The Indian Council for Medical Research said that the “product is ready,” and has a 97.3% success rate with no side effects, according to a report from the Hindustan Times. The contraceptive works via an injection to the vas deferens, the sperm-containing tube near the testicles. It contains a polymer called Steryene Maleic Anhydride, which was developed in the 1970s to inhibit sperm production. According to the report, the contraceptive will be effective for 13 years. VG Somani, the Drug Controller General of India, estimates approval of the drug to take around six months, minimum. “It’s the first in the world from India so we have to be extra careful about approval. We are looking at all aspects, especiall...
Read more

Novartis sickle-cell drug gets U.S. FDA approval

By John Miller and Carl O’Donnell (Reuters) - Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance. The drug will be priced between $84,852 and $113,136 per year for most patients, who will be infused by a healthcare provider with between three and four vials each month, Novartis said. The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo. The Food and Drug Administration’s approval came nearly two months ahead of its due date for a decision in January. Novartis has forecast that the drug’s annual sales will top $1 billion, much of which will likely come from U.S. government payers such as Medicare and Medicaid. The dru...
Read more